Decibel Therapeutics, Inc.
Decibel Therapeutics, Inc. (DBTX): 9 pipeline candidates · ~23 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
22.5 months
D/E 0.77 · 0% dilution
Lead: Phase 1
9 candidates
N/A
N/A
A transparent, data-derived signal for Decibel Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$39.8M
Quarterly Burn
$10.3M
Runway
22.5 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (9 candidates)
| Drug | Phase |
|---|---|
| aav.103 | Preclinical |
| aav.104 | Preclinical |
| aav.105 | Preclinical |
| aav.201 | Preclinical |
| articular hearing aids | — |
| articulate fitting system | — |
| db-020 | Phase 1 |
| db-ato | Preclinical |
| db-oto | Preclinical |
Frequently asked questions
How many drug candidates are in Decibel Therapeutics, Inc.'s pipeline?
Decibel Therapeutics, Inc. (DBTX) has 9 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Decibel Therapeutics, Inc.'s lead drug candidate?
Decibel Therapeutics, Inc.'s most advanced tracked candidate is aav.103 (Preclinical) for Hearing loss due to mutations in the GJB2 gene.
What is Decibel Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Decibel Therapeutics, Inc. has approximately 22.5 months of cash runway.
Who is the CEO of Decibel Therapeutics, Inc.?
Massachusetts April is the chief executive officer of Decibel Therapeutics, Inc. (DBTX).
Get the full picture on Decibel Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.